MEDI-545: Phase IIa started

AstraZeneca's MedImmune Inc. unit began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate multiple dose schedules of subcutaneous MEDI-545 in 80 patients. The partners are co-develo...